ReviewFrontiers in immunology2021
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Injectable Hydrogels for Local Pharmacokinetic Control in Solid Tumors: From Passive Reservoirs to Stimulus-Responsive Exposure Systems.ACS pharmacology & translational science · 2026Review
- In situ forming hydrogels for colorectal cancer therapy.Materials today. Bio · 2025Review
- Tailoring Therapy: Hydrogels as Tunable Platforms for Regenerative Medicine and Cancer Intervention.Gels (Basel, Switzerland) · 2025Review
- Chitosan-Glycerol Injectable Hydrogel for Intratumoral Delivery of Macromolecules.Gels (Basel, Switzerland) · 2025Article
- Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook.Journal of nanobiotechnology · 2025Review
- Hydrogels in Veterinary Vaccine Development: Types, Mechanisms, and Applications.Gels (Basel, Switzerland) · 2025Review
- Hydrogel systems for spatiotemporal controlled delivery of immunomodulators: engineering the tumor immune microenvironment for enhanced cancer immunotherapy.Frontiers in cell and developmental biology · 2024Review
- Antimicrobial Peptide MPX with Broad-Spectrum Bactericidal Activity Promotes Proper Abscess Formation and Relieves Skin Inflammation.Probiotics and antimicrobial proteins · 2023Article
- Cancer Immunotherapy Using Bioengineered Micro/Nano Structured Hydrogels.Advanced healthcare materials · 2023Review
- Bio-adhesive Macroporous Hydrogels for In Situ Recruitment and Modulation of Dendritic Cells.Cellular and molecular bioengineering · 2023Article
- Drug Delivery Systems for Localized Cancer Combination Therapy.ACS applied bio materials · 2023Review
- Current State of Cold Atmospheric Plasma and Cancer-Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Hydrogel systems for targeted cancer therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Self-Assembling Injectable Hydrogel for Controlled Drug Delivery of Antimuscular Atrophy Drug Tilorone.Pharmaceutics · 2022Article
- Developments on the Smart Hydrogel-Based Drug Delivery System for Oral Tumor Therapy.Gels (Basel, Switzerland) · 2022Review
- Chemical and Synthetic Biology Approaches for Cancer Vaccine Development.Molecules (Basel, Switzerland) · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy can boost the immune response of patients to eliminate tumor cells and suppress tumor metastasis and recurrence. However, immunotherapy resistance and the occurrence of severe immune-related adverse effects are clinical challenges that remain to be addressed. The tumor microenvironment plays a crucial role in the therapeutic efficacy of cancer immunotherapy. Injectable hydrogels have emerged as powerful drug delivery platforms offering good biocompatibility and biodegradability, minimal invasion, convenient synthesis, versatility, high drug-loading capacity, controlled drug release, and low toxicity. In this review, we summarize the application of injectable hydrogels as a unique platform for targeting the immunosuppressive tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.